8-KOther EventsExhibits & Filings

PFIZER INC 8-K Report, Corporate Update (Dec 19, 2017)

Filed December 19, 2017For Securities:PFE

Summary

Pfizer Inc. (PFE) announced the completion of its previously disclosed Exchange Offer and Tender Offer related to its outstanding £1,500,000,000 6.500% Notes due 2038. The offers aimed to exchange these notes for newly issued debt securities and repurchase them for cash. A significant portion of the 2038 Notes were tendered and accepted, with £833,450,000 principal amount accepted in the Exchange Offer and £196,550,000 in the Tender Offer, resulting in their cancellation. Following these offers, Pfizer issued £1,375,882,000 aggregate principal amount of new 2.735% Notes due 2043. This proactive debt management indicates Pfizer's strategy to refinance existing debt with new issuances bearing a lower interest rate, which could positively impact future interest expenses and cash flow. Approximately £470,000,000 of the original 2038 Notes remain outstanding.

Key Highlights

  • 1Pfizer successfully completed its Exchange Offer and Tender Offer for its 6.500% Notes due 2038.
  • 2A substantial principal amount of the 2038 Notes was either exchanged or tendered for purchase and cancelled.
  • 3Pfizer issued new debt: £1,375,882,000 in aggregate principal amount of 2.735% Notes due 2043.
  • 4The new notes carry a significantly lower interest rate (2.735%) compared to the old notes (6.500%), suggesting a refinancing strategy to reduce interest expense.
  • 5Approximately £470 million of the original 2038 Notes remain outstanding.
  • 6The new notes are unsecured general obligations of Pfizer, ranking equally with other unsecured and unsubordinated indebtedness.

Frequently Asked Questions

The primary purpose was to refinance Pfizer's outstanding £1,500,000,000 6.500% Notes due 2038. Pfizer sought to exchange these older, higher-interest notes for newly issued debt securities and also offered to purchase them back for cash.

A total of £1,030,000,000 (£833,450,000 from the Exchange Offer + £196,550,000 from the Tender Offer) of the 6.500% Notes due 2038 were accepted and cancelled. Pfizer issued £1,375,882,000 aggregate principal amount of new 2.735% Notes due 2043 in exchange.

This refinancing is expected to be beneficial as Pfizer is replacing debt with a higher interest rate (6.500%) with debt carrying a significantly lower interest rate (2.735%). This should lead to a reduction in future interest expenses, potentially improving profitability and free cash flow.

No, the New Notes have not been registered under the U.S. Securities Act of 1933. They may only be offered or sold outside the United States or to non-U.S. persons, unless offered in a transaction exempt from registration requirements.